Drug Profile
Research programme: CNS disorder therapeutics - Saniona
Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Saniona
- Developer Pfizer; Saniona
- Class Small molecules
- Mechanism of Action Ion channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - CNS disorders
Highest Development Phases
- Discontinued CNS disorders